SYDE2 is a Rho GTPase-activating protein (RhoGAP) that functions as a negative regulator of Rho-type GTPases by promoting their conversion to an inactive GDP-bound state 1. The protein facilitates cytoskeletal remodeling and cell migration processes 2, with expression regulated by multiple mechanisms including miRNA (miR-21-5p and miR-142-5p) and long non-coding RNA pathways 31. Clinically, SYDE2 demonstrates tumor-suppressive properties across multiple cancer types. In clear cell renal cell carcinoma (ccRCC), reduced SYDE2 expression correlates with poor prognosis and altered immune cell infiltration 3, while SYDE2 downregulation is independently associated with poorer survival outcomes in kidney renal clear cell carcinoma (KIRC) 1. In endometrial cancer, SYDE2 upregulation distinguishes both cancer patients from controls and advanced cancer cases from low-grade cases, implicating it in tumor growth pathways 4. Additionally, SYDE2 has been identified as a candidate gene in intellectual disability pathogenesis 5 and airway-localized molecular signatures of COPD 6, suggesting broader roles in development and pulmonary disease. These findings establish SYDE2 as a multi-functional protein with significant disease relevance across oncologic and non-oncologic conditions.